PDCD1 and neoplasm: In evaluating the efficacy and mechanism of A2aR inhibitor and anti‐PD‐1 monoclonal antibody combination, it was found that226: compared with monotherapy, this combination significantly reduced tumor metastasis and extended the lifespan of the mice.